Cargando…

Role of IL-12p40 in cervical carcinoma

BACKGROUND: Previously, we have shown that low IL-12p40 mRNA expression by cervical cancer cells is associated with a poor survival of cervical cancer patients. As IL-12p40 is both a subcomponent of interleukin (IL)-12 and IL-23, the aim of this study was to elucidate the role of IL-12p40 in cervica...

Descripción completa

Detalles Bibliográficos
Autores principales: Zijlmans, H J M A A, Punt, S, Fleuren, G J, Trimbos, J B, Kenter, G G, Gorter, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516683/
https://www.ncbi.nlm.nih.gov/pubmed/23099807
http://dx.doi.org/10.1038/bjc.2012.488
_version_ 1782252333613187072
author Zijlmans, H J M A A
Punt, S
Fleuren, G J
Trimbos, J B
Kenter, G G
Gorter, A
author_facet Zijlmans, H J M A A
Punt, S
Fleuren, G J
Trimbos, J B
Kenter, G G
Gorter, A
author_sort Zijlmans, H J M A A
collection PubMed
description BACKGROUND: Previously, we have shown that low IL-12p40 mRNA expression by cervical cancer cells is associated with a poor survival of cervical cancer patients. As IL-12p40 is both a subcomponent of interleukin (IL)-12 and IL-23, the aim of this study was to elucidate the role of IL-12p40 in cervical cancer. METHODS: We have measured the expression of IL-23p19 mRNA, IL-12p35 mRNA and IL-12p40 mRNA using mRNA in situ hybridisation. The IL-1 and IL-6 were measured by immunohistochemistry. RESULTS: As IL-23 is a component of the IL-17/IL-23 pathway, a pathway induced by IL-1 and IL-6 in humans, we have studied IL-1 and IL-6 expression. Only a high number of stromal IL-6-positive cells was shown to associate with poor disease-specific survival. The worst disease-specific survival was associated with a subgroup of patients that displayed a high number of IL-6-positive cells and low IL-12p40 expression (P<0.001). Both a high number of IL-6-positive cells and a high number of IL-6-positive cells, plus low IL-12p40 expression were shown to be clinicopathological parameters independent of lymph node metastasis, parametrial involvement and Sedlis score (P=0.009 and P=0.007, respectively). CONCLUSION: Our results with IL-6 and IL-12p40 are in accordance with the hypothesis that the IL-17/IL-23 pathway has a suppressive role in cervical cancer.
format Online
Article
Text
id pubmed-3516683
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-35166832013-12-04 Role of IL-12p40 in cervical carcinoma Zijlmans, H J M A A Punt, S Fleuren, G J Trimbos, J B Kenter, G G Gorter, A Br J Cancer Molecular Diagnostics BACKGROUND: Previously, we have shown that low IL-12p40 mRNA expression by cervical cancer cells is associated with a poor survival of cervical cancer patients. As IL-12p40 is both a subcomponent of interleukin (IL)-12 and IL-23, the aim of this study was to elucidate the role of IL-12p40 in cervical cancer. METHODS: We have measured the expression of IL-23p19 mRNA, IL-12p35 mRNA and IL-12p40 mRNA using mRNA in situ hybridisation. The IL-1 and IL-6 were measured by immunohistochemistry. RESULTS: As IL-23 is a component of the IL-17/IL-23 pathway, a pathway induced by IL-1 and IL-6 in humans, we have studied IL-1 and IL-6 expression. Only a high number of stromal IL-6-positive cells was shown to associate with poor disease-specific survival. The worst disease-specific survival was associated with a subgroup of patients that displayed a high number of IL-6-positive cells and low IL-12p40 expression (P<0.001). Both a high number of IL-6-positive cells and a high number of IL-6-positive cells, plus low IL-12p40 expression were shown to be clinicopathological parameters independent of lymph node metastasis, parametrial involvement and Sedlis score (P=0.009 and P=0.007, respectively). CONCLUSION: Our results with IL-6 and IL-12p40 are in accordance with the hypothesis that the IL-17/IL-23 pathway has a suppressive role in cervical cancer. Nature Publishing Group 2012-12-04 2012-10-25 /pmc/articles/PMC3516683/ /pubmed/23099807 http://dx.doi.org/10.1038/bjc.2012.488 Text en Copyright © 2012 Cancer Research UK https://creativecommons.org/licenses/by-nc-sa/3.0/From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
spellingShingle Molecular Diagnostics
Zijlmans, H J M A A
Punt, S
Fleuren, G J
Trimbos, J B
Kenter, G G
Gorter, A
Role of IL-12p40 in cervical carcinoma
title Role of IL-12p40 in cervical carcinoma
title_full Role of IL-12p40 in cervical carcinoma
title_fullStr Role of IL-12p40 in cervical carcinoma
title_full_unstemmed Role of IL-12p40 in cervical carcinoma
title_short Role of IL-12p40 in cervical carcinoma
title_sort role of il-12p40 in cervical carcinoma
topic Molecular Diagnostics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3516683/
https://www.ncbi.nlm.nih.gov/pubmed/23099807
http://dx.doi.org/10.1038/bjc.2012.488
work_keys_str_mv AT zijlmanshjmaa roleofil12p40incervicalcarcinoma
AT punts roleofil12p40incervicalcarcinoma
AT fleurengj roleofil12p40incervicalcarcinoma
AT trimbosjb roleofil12p40incervicalcarcinoma
AT kentergg roleofil12p40incervicalcarcinoma
AT gortera roleofil12p40incervicalcarcinoma